Abstract
Aim:
To explore the effects of heterodimerization of D2 receptor/A2a receptor (D2R/A2aR) on D2R internalization and D2R downstream signaling in primary cultured striatal neurons and HEK293 cells co-expressing A2aR and D2R in vitro.
Methods:
Primary cultured rat striatal neurons and HEK293 cells co-expressing A2aR and D2R were treated with A2aR- or D2R-specific agonists. D2R internalization was detected using a biotinylation assay and confocal microscopy. ERK, Src kinase and β-arrestin were measured using Western blotting. The interaction between A2aR and D2R was detected using bioluminescence resonance energy transfer (BRET) and immunoprecipitation.
Results:
D2R and A2aR were co-localized and formed complexes in striatal neurons, while both the receptors formed heterodimers in the HEK293 cells. In striatal neurons and the HEK293 cells, the D2R agonist quinpirole (1 μmol/L) marked increased Src phosphorylation and β-arrestin recruitment, thereby D2R internalization. Co-treatment with the A2aR antagonist ZM241385 (100 nmol/L) significantly attenuated these D2R-mediated changes. Furthermore, both ZM241385 (100 nmol/L) and the specific Src kinase inhibitor PP2 (5 μmol/L) blocked D2R-mediated ERK phosphorylation. Moreover, expression of the mutant β-arrestin (319-418) significantly attenuated D2R-mediated ERK phosphorylation in HEK293 cells expressing both D2R and A2aR, but not in those expressing D2R alone.
Conclusion:
A2aR antagonist ZM241385 significantly attenuates D2R internalization and D2R-mediated ERK phosphorylation in striatal neurons, involving Src kinase and β-arrestin. Thus, A2aR/D2R heterodimerization plays important roles in D2R downstream signaling.
Similar content being viewed by others
Introduction
Dopamine receptors are G protein-coupled receptors (GPCRs). These receptors can be divided into D1-like and D2-like families. D2 receptors belong to the D2-like family. The activation of D2R reduces cAMP expression1, extracellular signal-regulated kinase1/2 (ERK) phosphorylation2, phospholipase C activation3, and receptor internalization4,5,6.
Adenosine receptors are also GPCRs7. Dopamine D2 and Adenosine A2a receptors form heterodimers8,9,10. In D2R-cotransfected neuroblastoma cells, long-term exposure to A2aR and D2R agonists resulted in the co-aggregation, co-internalization, and co-desensitization of A2aR and D2R9. However, the modulation of D2R downstream signaling and internalization through A2aR has not been fully demonstrated.
The A2aR antagonist has been demonstrated to improve the effects of L-dopa and to reduce “off” time in clinical trials11,12,13. Because dopamine receptors play a key role in Parkinson's disease14, characterizing the modulation of D2R downstream signaling through A2aR would increase our understanding of the role of D2R/A2aR heterodimers in Parkinson's disease.
In the present study, we explored the ability of the A2aR antagonist ZM241385 in A2aR/D2R cotransfected cells and striatal neurons to attenuate the receptor internalization and ERK phosphorylation induced by the D2R agonist quinpirole; we also demonstrated the participation of Src kinase and β-arrestin in D2R internalization and ERK phosphorylation.
Materials and methods
Primary striatal neurons culture
Dissociated primary cultures of striatal neurons from embryonic d 18 (E18) rats were prepared from timed-pregnant Sprague Dawley rats as described previously, with minor modifications15. Briefly, the fetuses were removed under sterile conditions and maintained on iced D-Hank's solution for microscopic dissection of the striatum. The meninges were removed. The tissue was briefly minced and triturated using a fire-polished Pasteur pipette. The cells were counted and plated on six-well culture plates in DMEM containing 10% fetal bovine serum (FBS). After 5 h, the medium was replaced with serum-free B27/neurobasal medium supplemented with 0.5 mmol/L glutamine and antibiotics. The cultures were maintained at 37 °C in a humidified 5% CO2 atmosphere.
HEK293 cell culture
HEK293 cells were cultured at 37 °C and 5% CO2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS.
Co-immunoprecipitation and immunoblotting
Cell lysates were prepared after incubation in modified radioimmunoprecipitation assay (RIPA) lysis buffer (Tris-HCl 50 mmol/L, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 0.25% Na-deoxycholate, 1% NP-40, 1 mmol/L PMSF, 1 mmol/L Na3VO4, 1 mmol/L NaF, 10 μg/mL aprotinin, 5 μg/mL leupeptin, and 5 μg/mL pepstatin). The clarified lysates were subjected to SDS-PAGE and electrophoretically transferred to PVDF membranes as described previously15. The blots were incubated overnight at 4 °C with primary antibodies. After probing with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature, the immunoreactive proteins were visualized using an enhanced chemiluminescence kit (Pierce, Rockford, Illinois, USA). In some cases, the blots were stripped and reprobed with other antibodies.
Interactions between D2R and β-arrestin or A2aR were examined by coimmunoprecipitation. Briefly, the cells were prepared after incubation in Tx/G lysis buffer (300 mmol/L NaCl, 1% Triton X-100, 10% glycerol, 1.5 mmol/L MgCl2, 1 mmol/L CaCl2, 10 mmol/L EDTA and 50 mmol/L Tris, pH 7.4) containing 100 mmol/L iodoacetamide, 10 μg/mL aprotinin and 5 μg/mL leupeptin for 45 min on ice16. The clarified lysates were immunoprecipitated through overnight incubation at 4 °C using anti-D2R (Millipore, Bedford, MA, USA) or anti-A2aR antibodies (Millipore, Bedford, MA, USA), followed by incubation with Protein A/G-Sepharose beads (Santa Cruz, CA, USA). Equivalent amounts of protein were analyzed for each condition. The beads were washed three times with lysis buffer, and the immune complexes were boiled in SDS sample buffer and loaded onto SDS-PAGE gels for immunoblot analysis. The immunoreactive protein bands were detected using the enhanced chemiluminescence kit (Pierce, Rockford, Illinois, USA).
Biotinylation assays
Living striatal neurons or HEK293 cells were labeled for 20 min at 37 °C with EZ-link NHS-SS-biotin (300 μg/mL, Pierce, Rockford, Illinois, USA) to biotinylate the surface proteins17. After washing in PBS+MC, the cells were incubated in medium alone or medium containing different compounds for various times. Trafficking was terminated after rapid cooling to 4 °C. The biotinylated proteins remaining on the cell surface were stripped of biotin using the non-permeant reducing agent glutathione (150 mmol/L glutathione and 150 mmol/L NaCl, pH 8.75). Glutathione was subsequently neutralized with 50 mmol/L iodoacetamide in PBS+MC. The cells were incubated in RIPA buffer (50 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 1% SDS) for 30 min at 4 °C. After centrifugation at 16 000×g, supernatants containing equal amounts of total protein were incubated with streptavidin beads overnight at 4 °C to capture biotinylated proteins. After washing in extraction buffer, the samples were boiled in sample buffer to elute the biotinylated proteins from the streptavidin beads. The proteins were separated by SDS-PAGE and immunoblotted using antibodies against D2R (1:600), A2aR (1:4000, Millipore Bedford, MA, USA) or Myc (1:1000 Cell Signaling Technology, Beverly, MA, USA). The immunoblots were processed using a standard chemiluminescence protocol. Equal amount of proteins untreated with streptavidin beads were used for normalization.
Fluorescence internalization assay
HEK293 cells co-transfected with D2GFP/A2aRFP were first treated for 1 h with the indicated compounds, after which they were fixed with 4% paraformaldehyde (PFA). Fluorescence images were acquired using confocal microscopy (Olympus, Lake Success, NY, USA) and quantified with Image Pro Plus. Total fluorescence intensities (a) and cytoplasmic fluorescence intensities (b) were quantified separately. The percentage of cell surface protein was quantified as (a−b)/a×100%.
Immunofluorescence
Primary cultured striatal neurons were fixed with acetone, and after washing twice with PBS, the cells were blocked for 1 h in blocking buffer (5% normal goat serum and 1% BSA in PBS) before incubation with anti-D2R and anti-A2aR antibodies diluted in blocking buffer at 4 °C overnight. The cells were washed three times with PBS and incubated with Alexa Fluor 488 conjugated goat anti-rabbit IgG and Alexa Fluor 555 conjugated goat anti-mouse IgG (1:100) (Molecular probes, Eugene, OR, USA) for 1.5 h at room temperature. The images were captured using a confocal microscope (Olympus, Lake Success, NY, USA).
BRET assay
The plasmids were transfected into HEK293 cells. At 48 h after transfection, the culture medium was removed, and the cells were washed twice with PBS and subsequently resuspended in DPBS at a density of 3.2×105/mL. The cells were added into 384-well plate at 25 μL/well, and 25 μL of DeepBlueC solution was added to obtain a final concentration of 5 μmol/L DeepBlueC (Biotium, Hayworth, CA, USA). The plate was immediately read on a POLARstar Omega Microplate Reader (BMG GmbH, Offenburg, Germany) at EM 460 nm and 510/20 nm. The BRET ratio was calculated using the formula below (cells co-transfected with A2aRluc/pGFP were used as a blank):
BRET ratio=[(emission at 510/20 nm)−(emission at EM 460 nm)×Cf]/(emission at EM 460 nm)
(Cf=emission at 510 nm of blank/emission at 460 nm of blank).
Plasmid construction
Prof Jerrey L BENOVIC (Thomas Jefferson University) kindly provided β-arrestin (319–418). A1R-pcDNA3.1 was generated in our lab18. The other constructs were produced by PCR using specific primers. For D2GFP, the D2R fragments were generated by PCR, ligated into the expression vector pCDNA3.1 (Invitrogen, Carlsbad, CA, USA), and sequenced. The primers used were forward 5′-CCAAGCTTGCCACCATGGATCCACTGAATCTGTCCTGGT-3′ and reverse 5′-CCGGAATTCTCAGCAGTGGAGGATCTTCAGGA-3′.
The amplified fragments were fluorescently tagged at the carboxyl terminus using GFP. For D2Myc, the same D2R fragment was generated by PCR using the same primers and inserted into pcDNA3.1/myc-His A (Invitrogen, Carlsbad, CA, USA). For A2aRFP, the A2aR fragment was generated by PCR, ligated into the expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA), and sequenced. The primers used were forward 5′-CGGAATTCATGCCCATCATGGGCTCCTC-3′ and reverse 5′-GCTCTAGACTACAGCTCGTCCATGCCGA-3′. The amplified fragments were fluorescently tagged at the carboxyl terminus using RFP. Prof Jing-gen LIU (Shanghai Institute of Materia Medica, Chinese Academic of Science) kindly provided pGFP2-N3 and pRluc-N3. For D2pGFP2-N3, the D2R fragment was generated by PCR, ligated into the expression vector pGFP2-N3, and sequenced. The primers used were forward 5′-CCGGAATTCATGGATCCACTGAATCTGTCCTGGT-3′ and reverse 5′-CCAAGCTTGCAGTGGAGGATCTTCAGGAAGGCCTTG-3′. For A2aRluc-N3, the A2aR fragment was generated by PCR, ligated into the expression vector pRluc-N3, and sequenced. The forward and reverse primers were 5′-CCCTCGAGATGCCCATCATGGGCTCCTC-3′ and 5′-CCAAGCTTGGACACTCCTGCTCCATCCT-3′, respectively.
Statistics
The data were presented as the means±SEM and compared with one-way ANOVA followed by the Bonferroni post hoc test using the GraphPad InStat statistical program. The level of statistical significance was set at P<0.01 and P<0.05. The data were obtained from at least three separate experiments.
Results
D2R and A2aR form heterodimers
D2R and A2aR were highly expressed on striatopallidal neurons. To confirm the interaction between D2R and A2aR, immunofluorescence experiments were performed using primary cultured striatal neurons. The results showed that D2R and A2aR were co-localized on striatal neurons (Figure 1A). The co-immunoprecipitation results indicated that D2R and A2aR formed complexes on striatal neurons (Figure 1B). Furthermore, the BRET assay demonstrated that D2R and A2aR formed heterodimers on HEK293 cells (Figure 1C). These results suggested that D2R and A2aR co-localize and form heterodimers.
Quinpirole-induced internalization is attenuated upon combined treatment with ZM241385 and quinpirole
The long-term activation of D2R could lead to D2R internalization6. Internalization is important for regulating GPCR downstream signaling. A biotinylation assay and confocal microscopy were used to investigate the modulation of the A2aR agonist or antagonist on D2R internalization. DIV 9 striatal neurons were treated with the A2aR agonist CGS21680 or the D2R agonist quinpirole alone or in combination for 3 h, and the subsequent induction of A2aR and D2R co-internalization were observed (Figure 2A, 2B). Because A2aR and D2R form heterodimers, the activation of either the D2 or A2a receptor could induce the co-internalization of D2R/A2aR heterodimers, consistent with previously reported data9. The results also showed that the A2a receptor antagonist ZM241385 reduced D2 receptor internalization (Figure 2C).
To further confirm this result, the effects of A2aR on D2R internalization were also examined in HEK293 cells. Plasmids carrying D2GFP and A2aRFP were co-transfected into HEK293 cells. After treatment with different compounds, the cells were fixed with 4% paraformaldehyde, and images were captured using confocal microscopy (Olympus). The results showed that treatment with CGS21680 or quinpirole, separately or in combination, induced the co-internalization of the two receptors. In addition, ZM241385 reduced D2R quinpirole-induced internalization (Figure 3), consistent with the result obtained using striatal neurons.
D2R internalization occurs in a β-arrestin/clathrin- and Src kinase-dependent manner
Src kinase and β-arrestin are important for GPCR internalization. We used a surface biotinylation assay to characterize the role of Src kinase in D2R internalization. The results showed that striatal neurons treated with PP2, an Src kinase inhibitor, obviously inhibited quinpirole-induced D2R internalization (Figure 4A), suggesting that D2R internalization is Src kinase dependent.
Many GPCRs are internalized in a β-arrestin/clathrin-dependent manner. The dominant negative β-arrestin (319–418) mutant was used to determine the roles of β-arrestins in D2R internalization. This plasmid inhibited β-arrestin/clathrin-dependent receptor internalization through blocking the formation of the β-arrestin/clathrin complex19. We treated β-arrestin (319–418)-transfected HEK293 cells with the D2R agonist quinpirole to detect D2R internalization using Western blotting. The results showed that the expression of β-arrestin (319–418) in HEK293 cells inhibited quinpirole-induced D2R internalization, thereby demonstrating that β-arrestin was involved in D2R internalization (Figure 4B). These results were consistent with previously reported data2,4,6.
ZM241385 reduced D2R-induced Src kinase phosphorylation and β-arrestin 2 recruitment
Because Src kinase is involved in D2R internalization, this protein might also participate in the ZM241385-mediated modulation of D2R internalization. We used Western blotting to determine whether Src plays a role in the internalization of A2aR and D2R. The results indicated that the activation of D2R induces Src kinase phosphorylation in striatal neurons. ZM241385 also attenuated D2R-induced Src kinase phosphorylation (Figure 5A).
Moreover, the co-immunoprecipitation data showed that activated D2R recruited β-arrestin 2 to striatal neurons and that ZM241385 reduced D2R and β-arrestin 2 interactions (Figure 5B).
These results demonstrated that both Src kinase and β-arrestin are involved in D2R internalization and that ZM241385 reduces D2R-induced Src kinase phosphorylation and β-arrestin recruitment, resulting in the eventual reduction of D2R internalization.
ZM241385 reduced D2R-induced ERK phosphorylation
Extracellular regulated protein kinases (ERK1/2) are members of the mitogen-activated protein kinase (MAPK) family, which are involved in many important events, such as neuron survival and cell differentiation4. The activation of D2R induces ERK phosphorylation20. Thus, the roles of A2aR/D2R heterodimerization in D2R-induced ERK activation were also investigated.
Western blot analysis showed that the activation of A2aR did not affect D2R-induced ERK phosphorylation (Figure 6A), whereas ZM241385 reduced D2R-induced ERK phosphorylation in a dose-dependent manner (Figure 6B). These results were confirmed in HEK293 cells (Figure 6D).
Src kinase and β-arrestin participated in D2R-induced ERK phosphorylation when D2R was co-expressed with A2aR
D2R induces ERK activation in a G protein-dependent manner, and Src kinase participates in this activation2,4. However, the mechanism of ERK activation might be different under different conditions. The formation of heterodimers might affect receptor-induced ERK activation21. In some cases, signal proteins, such as β-arrestin, not only participate in receptor internalization but also are involved in ERK activation22,23.
Striatal neurons were treated with the Src kinase-specific inhibitor PP2, followed by treatment with the D2R agonist quinpirole. PP2 inhibited quinpirole-induced ERK phosphorylation (Figure 7), suggesting that Src kinase is involved in D2R-induced ERK phosphorylation, consistent with previously reported data2.
Some studies have implicated β-arrestin in mechanisms of the GPCR downstream signaling pathway, such as ERK phosphorylation21,22,24. The mutant β-arrestin (319–418) was used to investigate effects of β-arrestins in D2 receptor-induced ERK activation. The data showed that in HEK 293 cells expressing D2R alone, the expression of β-arrestin (319–418) did not affect quinpirole-induced ERK phosphorylation (Figure 8A), consistent with previous reports20. Interestingly, in HEK293 cells co-expressing D2R and A2aR, the expression of β-arrestin (319–418) attenuated quinpirole-induced ERK phosphorylation (Figure 8B), whereas β-arrestin (319–418) expression in HEK293 cells co-expressing D2R and A1R did not affect quinpirole-induced ERK phosphorylation (Figure 8C). These results suggested that D2R/A2aR heterodimerization changed D2R-induced ERK phosphorylation.
Taken together, these results showed that Src kinase (Figure 7) and β-arrestin (Figure 8) are involved in D2R-induced ERK activation and that ZM241385 reduces D2R-induced Src kinase phosphorylation and β-arrestin recruitment (Figure 5), thereby reducing D2R-induced ERK activation through ZM241385 (Figure 6).
Discussion
D2R and A2aR form heterodimers, and the activation of either D2R or A2aR results in the co-internalization of D2R/A2aR heterodimers9. The results of the present study confirmed these observations in striatal neurons and HEK293 cells co-expressing D2R/A2aR. The activation of A2aR induced the co-internalization of D2R/A2aR heterodimers, whereas ZM241385 reduced D2R internalization, indicating that D2R/A2aR receptor heterodimerization affects D2R internalization.
The present study also demonstrated that after activation, D2R is internalized through a β-arrestin/clathrin-dependent pathway involving Src kinase. Western blot analysis revealed that ZM241385 reduces D2R-induced Src kinase phosphorylation, and co-immunoprecipitation showed that ZM241385 reduces the D2R-mediated recruitment of β-arrestin2. These results indicated that ZM241385 reduces D2R-induced Src kinase phosphorylation and the recruitment of β-arrestin2, thereby reducing D2R internalization. Fuxe et al demonstrated that A2aR activation enhances D2R binding with β-arrestin2 and that D2R, A2aR, and β-arrestin2 might form a complex25. In the present study, we showed that ZM241385 reduces the D2R-mediated recruitment of β-arrestin2. Thus, it is possible that A2aR is involved in the interaction of β-arrestin2 and D2R/A2aR heterodimers. ZM241385 maintains A2aR in an inactive status26,27 and affects the interaction between D2R/A2aR heterodimer and β-arrestin2, thereby reducing D2R internalization. Clinical studies have shown that the A2aR antagonist prolongs the effective time and shortens the “off time” of L-dopa11,28, potentially reflecting D2R internalization.
In this study, we showed that the A2aR antagonist reduces D2R-induced Src kinase phosphorylation and β-arrestin2 recruitment; thus, the A2aR antagonist might not only reduce D2R internalization but also modulate D2R downstream signaling. The results in the present study also showed that D2R-induced ERK activation is Src kinase dependent. Moreover, the expression of the mutant β-arrestin (319–418) also reduced D2R-induced ERK activation when D2R was co-expressed with A2aR, suggesting that both Src kinase and β-arrestin participate in D2R-induced ERK activation. The A2aR antagonist reduces D2R-induced Src kinase phosphorylation and β-arrestin2 recruitment; thus, the A2aR antagonist might also reduce D2R-induced ERK activation.
Interestingly, β-arrestin was also involved in D2R-induced ERK phosphorylation when D2R was co-expressed with A2aR, but not when D2R was expressed alone. ERK phosphorylation might be influenced by many factors, and receptor dimerization might also influence ERK activation21. To our knowledge, most studies on D2R-induced ERK activation have utilized cells expressing D2R alone, showing that the expression of β-arrestin (319–418) had no effects on D2R-induced ERK activation20; these results were also confirmed in the present study. However, when D2R and A2aR were co-expressed, β-arrestin participated in D2R-induced ERK activation. In vivo, particularly in the striatum, D2R exists not only as a monomer or homodimer but also as a D2R/A2aR heterodimer9. Thus, the results of the present study enhance the current understanding of the mechanism underlying D2R-induced ERK activation under physiological conditions. Different mechanisms of ERK activation might exert different downstream effects. Distinguishing D2R monomer-induced ERK phosphorylation from D2R/A2a R heterodimer-induced ERK activation is difficult, as the development of a system containing only D2R/A2aR receptor heterodimers and no D2R monomers is not easy. However, this study showed the importance of heterodimers in receptor downstream signaling pathway.
Thus, this study showed that D2R and A2aR co-internalize. The A2aR antagonist reduced D2R-induced Src kinase phosphorylation and β-arrestin2 recruitment, thereby reducing D2R internalization and ERK phosphorylation. These observations showed that D2R/A2aR heterodimers play an important role in D2R signaling pathway and trafficking.
Author contribution
Lin-yin FENG and Li HUANG designed the research; Li HUANG, Dong-dong WU, and Lei ZHANG performed the research; Li HUANG analyzed the data; and Lin-yin FENG and Li HUANG wrote the paper.
References
Stoof JC, Kebabian JW . Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 1981; 294: 366–8.
Kim SJ, Kim MY, Lee EJ, Ahn YS, Baik JH . Distinct regulation of internalization and mitogen-activated protein kinase activation by two isoforms of the dopamine D2 receptor. Mol Endocrinol 2004; 18: 640–52.
Kanterman RY, Mahan LC, Briley EM, Monsma FJ Jr, Sibley DR, Axelrod J, et al. Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Mol Pharmacol 1991; 39: 364–9.
Neve KA, Seamans JK . Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 2004; 24: 165–205.
Beaulieu JM, Gainetdinov RR . The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 182–217.
Skinbjerg M, Ariano MA, Thorsell A, Heilig M, Halldin C, Innis RB, et al. Arrestin3 mediates D2 dopamine receptor internalization. Synapse 2009; 63: 621–4.
Ralevic V, Burnstock G . Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413–92.
Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR, et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 2003; 278: 46741–9.
Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002; 277: 18091–7.
Ferre S, Quiroz C, Woods AS, Cunha R, Popoli P, Ciruela F, et al. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des 2008; 14: 1468–74.
LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces «off» time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008; 63: 295–302.
Hauser RA, Hubble JP, Truong DD . Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003; 61: 297–303.
Hauser RA, Schwarzschild MA . Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging 2005; 22: 471–82.
Hurley MJ, Jenner P . What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther 2006; 111: 715–28.
Xie KQ, Zhang LM, Cao Y, Zhu J, Feng LY . Adenosine A1 receptor-mediated transactivation of the EGF receptor produces a neuroprotective effect on cortical neurons in vitro. Acta Pharmacol Sin 2009; 30: 889–98.
Jordan BA, Devi LA . G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999; 399: 697–700.
Liu Y, Tao YM, Woo RS, Xiong WC, Mei L . Stimulated ErbB4 internalization is necessary for neuregulin signaling in neurons. Biochem Biophys Res Commun 2007; 354: 505–10.
Cao Y, Sun WC, Jin L, Xie KQ, Zhu XZ . Activation of adenosine A1 receptor modulates dopamine D1 receptor activity in stably cotransfected human embryonic kidney 293 cells. Eur J Pharmacol 2006; 548: 29–35.
Krupnick JG, Santini F, Gagnon AW, Keen JH, Benovic JL . Modulation of the arrestin-clathrin interaction in cells. Characterization of beta-arrestin dominant-negative mutants. J Biol Chem 1997; 272: 32507–12.
Quan W, Kim JH, Albert PR, Choi H, Kim KM . Roles of G protein and beta-arrestin in dopamine D2 receptor-mediated ERK activation. Biochem Biophys Res Commun 2008; 377: 705–9.
Rozenfeld R, Devi LA . Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by — opioid receptor heterodimers. FASEB J 2007; 21: 2455–65.
DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK . β-Arrestins and cell signaling. Annu Rev Physiol 2007; 69: 483–510.
Ceresa BP, Schmid SL . Regulation of signal transduction by endocytosis. Curr Opin Cell Biol 2000; 12: 204–10.
Violin JD, Lefkowitz RJ . Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 2007; 28: 416–22.
Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, Ciruela F, Agnati LF, Fuxe K . On the existence of a possible A2A-D2-beta-Arrestin2 complex: A2A agonist modulation of D2 agonist-induced beta-arrestin2 recruitment. J Mol Biol 2011; 406: 687–99.
Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008; 322: 1211–7.
Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AG, et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 2011; 474: 521–5.
Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M . Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 2010; 25: 1437–43.
Acknowledgements
This work was supported by research grants from the National Natural Science Foundation of China (81123004) and the Chinese Academy of Sciences (XDA01040304).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, L., Wu, Dd., Zhang, L. et al. Modulation of A2a receptor antagonist on D2 receptor internalization and ERK phosphorylation. Acta Pharmacol Sin 34, 1292–1300 (2013). https://doi.org/10.1038/aps.2013.87
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/aps.2013.87
Keywords
This article is cited by
-
Antipsychotic-Like Efficacy of Dopamine D2 Receptor-Biased Ligands is Dependent on Adenosine A2A Receptor Expression
Molecular Neurobiology (2018)
-
Reduced sleep duration mediates decreases in striatal D2/D3 receptor availability in cocaine abusers
Translational Psychiatry (2016)
-
Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain
Translational Psychiatry (2015)